Document is current

Article History

Received: 3 December 2022

Revised: 17 February 2023

Accepted: 23 February 2023

First Online: 31 March 2023

Declarations

:

: Not applicable.

: MDC has been or is a current consultant for Sanofi-Genzyme, Novartis, Celgene Corp (Bristol Myers Squibb), Vifor Pharma, and Ionis Pharmaceuticals, and has received research funding from Sanofi-Genzyme, Novartis, Celgene Corp (Bristol Myers Squibb), La Jolla Pharmaceutical Company, Roche, Protagonist Therapeutics, and CRISPR Therapeutics. AK has received advisory board fees from Agios Pharmaceuticals, AMGEN, Celgene (Bristol Myers Squibb), Crisp/Vertex, Ionis, Novartis, Vifor Pharma; speaker fees from Celgene (Bristol Myers Squibb), Chiesi, Crisp/Vertex, Novartis, Vifor Pharma; and research funding from Celgene (Bristol Myers Squibb), Novartis. IM has received advisory board fees from Bristol Myers Squibb, Sanofi Genzyme, Amicus Therapeutics, and speaker fees from Bristol Myers Squibb, Sanofi Genzyme.